Guangfu Li, PhD

Profile

Dr. Guangfu Li is studying liver fibrosis, liver cancer, pancreatic cancer and lung cancer. Using cells, animal models and human biopsies, Dr. Li focuses on elucidating the underlying mechanisms mediating fibrosis, tumor growth and metastasis and tumor-induced immune tolerance. Based on the findings, Dr. Li aims to develop effective molecularly targeted diagnosis, molecularly targeted therapy and immunotherapy.

Academic Information

Assistant Professor

Office

One Hospital Drive
Columbia, MO 65212
United States

P. 573-882-7124

Research Interests

  • Mechanisms of tumor growth, tumor metastasis and tumor‐induced immunotolerance
  • Gut microbiome and liver disease
  • Immune‐based antitumor therapy
  • Molecularly targeted therapy
  • Molecularly targeted diagnosis
  • Tumor animal model Circulating tumor cell (CTC) Circulating tumor DNA (ctDNA)

Areas of Expertise

  • Cancer molecularly targeted therapy
  • Cancer immune-based therapy
  • Cancer early diagnosis

Education & Training

Post-Graduate School

2004, PhD, Nanjing Medical University, Nanjing China

Publications

  1. Guangfu Li, Dai Liu, Eric T Kimchi, Jussuf  T. Kaifi, Xiaoqiang Qi,  Tye Deering, Todd Fox, Don C. Rockey, Todd D Schell6, Mark Kester, Kevin F Staveley-O’Carroll, Immunotherapeutic Role of Nanoliposomal C6-Ceramide in Hepatocellular Cancer, Gastroenterology, 2018 Jan 31. pii: S0016-5085(18)30099-4. doi: 10.1053/j.gastro.2017.10.050. [Epub ahead of print]  (Corresponding author)
  2. Li-Qun Gu, Kent S. Gates, Michael X. Wang, Guangfu LiWhat is the potential of nanolock- and nanocross-nanopore technology in cancer diagnosis?, Expert Review of Molecular Diagnostics, 2017, DOI: 10.1080/14737159.2018.1410060
  3. Dai Liu, Guangfu Li, Diego M. Avella, Eric T. Kimchi, Jussuf T. Kaifi1, Mark P. Rubinstein, E. Ramsay Camp, Don C. Rockey, Todd D. Schell, Kevin F. Staveley-O’Carroll, Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancerOncoimmunology.2017 Sep 21;7(1):e1372079. doi: 10.1080/2162402X.2017.1372079. eCollection 2017 (co-first author and corresponding author)
  4. Dai Liu,Xiaoqiang Qi,  Yariswamy Manjunath, Eric T. Kimchi,Jussuf T. Kaifi, Kevin F. Staveley-O’Carroll, Guangfu LiSunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer,Journal of Immunology Research and Therapy, August, 2017, 2 (2): 115-123, (Corresponding author)
  5. Wang, Yong; Tian, Kai; Shi, Ruicheng; Gu, Amy; Pennella, Michael; Alberts, Lindsey ; Gates, Kent; Li, Guangfu; Fan, Hongxin; Wang, Michael; Gu, Li-Qun, Nanolock-Nanopore facilitated digital diagnostics of cancer driver mutation in tumor tissue,ACS Sensors, July 5, 2017, DOI: 10.1021/acssensors.7b00235
  6. Jingyu Zhang, Dai Liu, Guangfu Li, Kevin F. Staveley-O'Carroll, Julie N. Graff, Zihai Li1, and Jennifer D. Wu, Antibody targeting soluble NKG2D ligand sMIC remarkably enhances CTLA4 blockade therapy, ScienceAdvances, 17 May, 2017;3: e1602133
  7. Qian DLu Z2, Xu QWu PTian LZhao LCai BYin JWu YStaveley-O'Carroll KF4, Jiang KMiao Y6, Li GGalectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasisCancer Lett.2017 Mar 20. pii: S0304-3835(17)30198-2. doi: 10.1016/j.canlet.2017.03.024. [Epub ahead of print] (Corresponding author)
  8. Guangfu Li, Yue Huang, Yariswamy Manjunath, Eric T. Kimchi, Jussuf T. Kaifi, Kevin F. Staveley-O’Carroll,Clinical Significance of Circulating Tumor Cells in Pancreatic Cancer, Biol Med, 2016, 8:7, DOI: 10.4172/0974-8369.1000357(Corresponding author)
  9. Qian MaoPing-Hu ZhangJie YangJin-Di XuMing KongHong ShenHe Zhu,Min BaiLi ZhouGuangfu LiQiang Wang, and Song-Lin LiiTRAQ-based proteomic analysis of ginsenoside F2 on human gastric carcinoma cells,Evid Based Complement Alternat Med. 2016; 2016: 2635483.doi:10.1155/2016/2635483
  10. Guangfu Li, Dai Liu, Timothy K Cooper, Eric T Kimchi,Ningfei Li, Diego M Avella, Harriet C Isom,Qing Yang, Mark Kester, C. Bart Rountree, Todd D Schell, Kevin F Staveley-O’Carroll, Successful Chemoimmunotherapy against Hepatocellular Cancer in a Novel Murine Mode,J Hepatol.2016 Aug 9. pii: S0168-8278(16)30420-2. doi: 10.1016/ j.jhep.2016.07.044. [Epub ahead of print] (Corresponding author)
  11. Xiaoqiang Qi, Samuel SK Lam, Dai Liu, Dae Young Kim, Lixin Ma5 Lu Alleruzzo, Wei Chen, Tomas Hode, Carolyn J Henry, Jussuf Kaifi, Eric T Kimchi, Guangfu Li, and Kevin F Staveley-O’Carroll, Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer, J Clin Cell Immunol, 2016, 7:4 (Corresponding author)
  12. Li G, Staveley-O’Carroll KF, Kimchi ET (2016), Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Trials, 6:2. doi:10.4172/2167-0870.1000257 (Corresponding author)
  13. Jussuf T. KaifiGuangfu LiGary ClawsonEric T. KimchiKevin F. Staveley-O'CarrollPerioperative circulating tumor cell detection: current perspectives, Cancer Biol Ther, published online First April 5, 2016, DOI: 10.1080/15384047.2016.1167296
  14. Hephzibah Rani S. Tagaram, Dhimant Desai, Guangfu Li, Dai Liu, C. Bart Rountree, Kavitha Gowda, Arthur Berg, Shantu Amin, Kevin F. Staveley-O’Carroll and Eric T. Kimchi, A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer, Pharmaceutials, 2016, 9(2), 18; doi: 10.3390/ph9020018
Download All Publications Download